β-catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Sinnberg, Tobias ^a   Menzel, Moritz ^a   Ewerth, Daniel ^a   Sauer, Birgit ^a   Schwarz, Michael ^a   Schaller, Martin ^a   Garbe, Claus ^a   Schittek, Birgit ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CISPLATIN; DOXORUBICIN; DOXYCYCLINE; PKF 115 584; SHORT HAIRPIN RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PERYLENE; PKF115 584; PKF115-584; T CELL FACTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; MELANOCYTE; MELANOMA; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CELL STRAIN HCT116; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG SYNERGISM; HCT116 CELLS; HUMANS; MALE; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; PERYLENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051738374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023429     Document Type: Article

References (58)

1. Liu C, Li Y, Semenov M, Han C, Baeg GH, et al. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-847.
2. Xing Y, Clements WK, Kimelman D, Xu W, (2003) Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. Genes Dev 17: 2753-2764.
3. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
4. Morin PJ, (1999) beta-catenin signaling and cancer. Bioessays 21: 1021-1030.
5. Fang D, Leishear K, Nguyen TK, Finko R, Cai K, et al. (2006) Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells 24: 1668-1677.
6. Lang D, Lu MM, Huang L, Engleka KA, Zhang M, et al. (2005) Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433: 884-887.
7. Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, et al. (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21: 2923-2935.
8. Curley DP, Bosenberg MW, (2008) A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin. Pigment Cell Melanoma Res 21: 5-6.
9. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER, (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154: 325-329.
10. Omholt K, Platz A, Ringborg U, Hansson J, (2001) Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 92: 839-842.
11. Giles RH, van Es JH, Clevers H, (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24.
12. Larue L, Delmas V, (2006) The WNT/Beta-catenin pathway in melanoma. Front Biosci 11: 733-742.
13. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, et al. (2003) Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 103: 652-656.
14. Moon RT, Kohn AD, De Ferrari GV, Kaykas A, (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
15. Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, et al. (2002) Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158: 1079-1087.
16. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, et al. (2009) Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 106: 1193-1198.
17. Takahashi Y, Nishikawa M, Suehara T, Takiguchi N, Takakura Y, (2008) Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int J Cancer 123: 2315-2320.
18. O'Connell MP, Weeraratna AT, (2009) Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res 22: 724-739.
19. Bellei B, Flori E, Izzo E, Maresca V, Picardo M, (2008) GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal 20: 1750-1761.
20. Lucero OM, Dawson DW, Moon RT, Chien AJ, (2010) A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12: 314-318.
21. Sinnberg T, Menzel M, Kaesler S, Biedermann T, Sauer B, et al. (2010) Suppression of Casein Kinase 1a in Melanoma Cells Induces a Switch in β-Catenin Signaling to Promote Metastasis. Cancer Res 70: 6999-7009.
22. Hsu M-YEDHM, (1999) Melanoma: The Wistar Melanoma (WM) Cell Lines. In: Masters JaPB, editors. Human Cell Culture, Vol I Kluwer Academic Publishers pp. 259-274.
23. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, et al. (2007) The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120: 2110-2118.
24. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
25. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91-102.
26. Tallarida RJ, (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872.
27. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650-653.
28. Tepera SB, McCrea PD, Rosen JM, (2003) A beta-catenin survival signal is required for normal lobular development in the mammary gland. J Cell Sci 116: 1137-1149.
29. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, et al. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 104: 7516-7521.
30. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, et al. (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667.
31. Lapham A, Adams JE, Paterson A, Lee M, Brimmell M, et al. (2009) The Bcl-w promoter is activated by beta-catenin/TCF4 in human colorectal carcinoma cells. Gene 432: 112-117.
32. Bahmanyar S, Kaplan DD, Deluca JG, Giddings TH Jr, O'Toole ET, et al. (2008) beta-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev 22: 91-105.
33. Huang P, Senga T, Hamaguchi M, (2007) A novel role of phospho-beta-catenin in microtubule regrowth at centrosome. Oncogene 26: 4357-4371.
34. Kaplan DD, Meigs TE, Kelly P, Casey PJ, (2004) Identification of a role for beta-catenin in the establishment of a bipolar mitotic spindle. J Biol Chem 279: 10829-10832.
35. Daugherty RL, Gottardi CJ, (2007) Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda) 22: 303-309.
36. Hsu MY, Wheelock MJ, Johnson KR, Herlyn M, (1996) Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1: 188-194.
37. Nelson WJ, Nusse R, (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487.
38. Li G, Fukunaga M, Herlyn M, (2004) Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. Exp Cell Res 297: 142-151.
39. Medrek C, Landberg G, Andersson T, Leandersson K, (2009) Wnt-5a-CKI{alpha} signaling promotes {beta}-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J Biol Chem 284: 10968-10979.
40. Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, et al. (2001) Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun 288: 8-15.
41. Qi J, Chen N, Wang J, Siu CH, (2005) Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell 16: 4386-4397.
42. Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, et al. (2009) Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 82: 165-175.
43. Jansen SR, Van Ziel AM, Baarsma HA, Gosens R, (2010) {beta}-Catenin regulates airway smooth muscle contraction. Am J Physiol Lung Cell Mol Physiol 299: L204-L214.
44. Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y, (2010) NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene 29: 2540-2549.
45. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, et al. (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68: 650-656.
46. Posthaus H, Williamson L, Baumann D, Kemler R, Caldelari R, et al. (2002) beta-Catenin is not required for proliferation and differentiation of epidermal mouse keratinocytes. J Cell Sci 115: 4587-4595.
47. Fukunaga Y, Liu H, Shimizu M, Komiya S, Kawasuji M, Nagafuchi A, (2005) Defining the roles of beta-catenin and plakoglobin in cell-cell adhesion: isolation of beta-catenin/plakoglobin-deficient F9 cells. Cell Struct Funct 30: 25-34.
48. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, et al. (2010) Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12: 326-335.
49. Wei W, Chua MS, Grepper S, So S, (2010) Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 126: 2426-2436.
50. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, et al. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. PNAS 104: 7516-7521.
51. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, et al. (1997) Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7 (Suppl 2): S35-S42.
52. Herlyn D, Iliopoulos D, Jensen PJ, Parmiter A, Baird J, et al. (1990) In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res 50: 2296-2302.
53. Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, et al. (2003) Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. Exp Dermatol 12: 296-306.
54. Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, et al. (2000) Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 156: 193-200.
55. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ, (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A 73: 3278-3282.
56. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, et al. (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129: 1500-1515.
57. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, et al. (2008) Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128: 2013-2023.
58. Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, et al. (2006) LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 12: 1191-1197.